Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Keeps “Pre-Cold” With NAD Ad Victory

This article was originally published in The Tan Sheet

Executive Summary

Matrixx’s use of “The Pre-Cold Medicine” in the context of the challenged ads does not “reasonably convey a message that Zicam is effective in preventing colds or should be used by consumers for that purpose,” the National Advertising Review Board says.

You may also be interested in...



Boots' Symptoms Claim For Dual Defence Not A Prevention Pitch – UK Regulator

Boots UK’s display ad for its Dual Defense cold and flu symptom nasal spray was unlikely to deceive consumers to think it could prevent infection, UK Advertising Standards Authority says, which found that text in a poster ad sufficiently "conceptualized" the claim.

Supplement Claims On Duration Of Cold, Menopausal Support Fail In UK Reviews

The Advertising Standards Authority says Swedish firm Enymatica misses the mark for supporting ColdZyme supplement claims and UK firm PharmaCare’s ads for the Promensil menopause symptoms supplement run afoul of the rule it cites as support.

Zicam Creates A Monster With Reanimated Brand

Matrixx aims to make more consumers aware they can shorten the duration of a cold rather than treat the symptoms without affecting how long the cold lasts. New advertising introduces the “Cold Monster” to remind consumers to use Zicam products when they feel the first signs of a “monster of a cold.”

Topics

Related Companies

UsernamePublicRestriction

Register

PS106579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel